Search research articles
Contact Us
Filters
Showing results (601-610 of 636) with videos related to
Page
of 64
Sort By:
Metabolism: Clinical and Experimental
|
November 29, 2023
Rising global burden of cancer attributable to high BMI from 2010 to 2019
Darren Jun Hao Tan, Cheng Han Ng, Mark Muthiah, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
June 6, 2025
Deep Learning Reveals Liver MRI Features Associated With PNPLA3 I148M in Steatotic Liver Disease
Yazhou Chen, Benjamin P M Laevens, Teresa Lemainque, et al.
Journal of Hepatology
|
May 7, 2025
High inherited risk predicts age-associated increases in fibrosis in patients with MASLD
Luis Antonio Díaz, William Alazawi, Saaket Agrawal, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 10, 2024
Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma
Rebecca Wenling Zeng, Christen En Ya Ong, Elden Yen Hng Ong, et al.
Advances in Therapy
|
August 24, 2023
Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Daniel Q Huang, Veeral Ajmera, Christian Tomaszewski, et al.
Plos One
|
April 15, 2022
Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms
Tinsay A Woreta, Mark L Van Natta, Mariana Lazo, et al.
Hepatology (Baltimore, Md.)
|
February 11, 2021
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH
Amaro Taylor-Weiner, Harsha Pokkalla, Ling Han, et al.
Journal of Hepatology
|
April 15, 2018
Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis
Katharina Brandl, Phillipp Hartmann, Lily J Jih, et al.
The New England Journal of Medicine
|
February 7, 2024
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, et al.
Nature Reviews. Gastroenterology & Hepatology
|
September 27, 2025
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease
Luis Antonio Diaz, Maja Thiele, Alexandre Louvet, et al.
Page
of 64
Search research articles
Search
Showing results (601-610 of 636) with videos related to
Sort By:
Page
of 64
Metabolism: Clinical and Experimental
|
November 29, 2023
Rising global burden of cancer attributable to high BMI from 2010 to 2019
Darren Jun Hao Tan, Cheng Han Ng, Mark Muthiah, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
June 6, 2025
Deep Learning Reveals Liver MRI Features Associated With PNPLA3 I148M in Steatotic Liver Disease
Yazhou Chen, Benjamin P M Laevens, Teresa Lemainque, et al.
Journal of Hepatology
|
May 7, 2025
High inherited risk predicts age-associated increases in fibrosis in patients with MASLD
Luis Antonio Díaz, William Alazawi, Saaket Agrawal, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 10, 2024
Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma
Rebecca Wenling Zeng, Christen En Ya Ong, Elden Yen Hng Ong, et al.
Advances in Therapy
|
August 24, 2023
Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Daniel Q Huang, Veeral Ajmera, Christian Tomaszewski, et al.
Plos One
|
April 15, 2022
Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms
Tinsay A Woreta, Mark L Van Natta, Mariana Lazo, et al.
Hepatology (Baltimore, Md.)
|
February 11, 2021
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH
Amaro Taylor-Weiner, Harsha Pokkalla, Ling Han, et al.
Journal of Hepatology
|
April 15, 2018
Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis
Katharina Brandl, Phillipp Hartmann, Lily J Jih, et al.
The New England Journal of Medicine
|
February 7, 2024
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, et al.
Nature Reviews. Gastroenterology & Hepatology
|
September 27, 2025
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease
Luis Antonio Diaz, Maja Thiele, Alexandre Louvet, et al.
Page
of 64